RNAC
NASDAQ HealthcareCartesian Therapeutics, Inc. - Common Stock
Biotechnology
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
�� 市场数据
| 价格 | $7.04 |
|---|---|
| 成交量 | 373,253 |
| 市值 | 186.62M |
| 贝塔系数 | 0.560 |
| RSI（14日） | 70.0 超买 |
| 200日均线 | $8.68 |
| 50日均线 | $6.82 |
| 52周最高 | $15.57 |
| 52周最低 | $5.60 |
| Forward P/E | -4.17 |
| Price / Book | -1.45 |
🎯 投资策略评分
RNAC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (83/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RNAC in your text
粘贴任何文章、记录或帖子 — 工具将提取 RNAC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.